CN-121971463-A - Application of etoposide in preparation of anti-rabies virus drugs

Abstract

The invention discloses an application of etoposide in preparing anti-rabies virus drugs, which proves that the clinical anti-tumor drug etoposide has remarkable anti-rabies virus activity on the cellular and animal level for the first time, and plays an antiviral role in vivo and in vitro by inhibiting virus replication and reducing virus gene and protein expression. The novel medicine application of etoposide is provided for preparing novel medicines and technical schemes for treating rabies viruses, and has important significance for overcoming the clinical treatment difficulty of rabies.

Inventors

• GUO JIANXIONG
• LIU YAN
• ZHANG WENJIANG
• LIU YANBIN
• ZHANG CUILING
• WANG JIE
• YANG LIANHUA
• LI DAPENG

Assignees

• 军事科学院军事医学研究院军事兽医研究所

Dates

Publication Date

20260505

Application Date

20251209

Claims (6)

1. 1. Application of etoposide in preparing anti-rabies virus medicines.
2. 2. The use of claim 1, wherein the antiviral means of the medicament comprises inhibiting the replication of rabies virus in intracellular nucleic acids and the expression of viral M protein.
3. 3. A medicament for treating rabies, which is characterized by comprising etoposide.
4. 4. The medicament for treating rabies according to claim 3, further comprising pharmaceutically acceptable excipients and carriers.
5. 5. The rabies treating drug according to claim 4, wherein the adjuvant is selected from at least one of filler, disintegrant, binder, excipient, diluent, lubricant, sweetener or colorant.
6. 6. A medicament for treating rabies according to claim 3, wherein the dosage form of the medicament is selected from at least one of granules, tablets, pills, capsules, injections or dispersing agents.

Description

Application of etoposide in preparation of anti-rabies virus drugs Technical Field The invention relates to the field of new application of medicines, in particular to application of etoposide in preparation of anti-rabies virus medicines. Background Etoposide (Etoposide), also known as VP-16, has the chemical name 4' -demethyl epipodophyllotoxin-beta-D-ethylidene glucopyranoside. Is a broad-spectrum and high-efficiency antitumor drug, and belongs to semisynthetic derivatives of podophyllotoxin. Podophyllotoxins are initially natural products extracted from podophyllum plants, but are too toxic. By modifying the chemical structure of podophyllotoxin, etoposide with lower toxicity and better curative effect is obtained. The core target of etoposide has been reported to be DNA topoisomerase II, which, by binding and stabilizing the topoisomerase II and DNA complex, prevents the re-ligation of DNA breaks, resulting in DNA damage, and this "frozen" cleavage complex causes permanent damage to cells. When DNA replication forks encounter these stable complexes during replication, DNA double strand breaks are initiated, and numerous, unrepairable DNA double strand breaks activate intracellular apoptosis signaling pathways (programmed death), ultimately leading to cell death. It is etoposide, which converts topoisomerase II into a cytotoxin, causing DNA double strand breaks, which has been developed as an antitumor drug for inhibiting tumor cell proliferation and apoptosis, and has been widely used in clinic. For example, etoposide in combination with platinum (e.g., cisplatin or carboplatin) is a first line standard chemotherapy regimen for the treatment of small cell lung cancer, BEP regimens with bleomycin and cisplatin are classical regimens for the treatment of metastatic germ cell tumors (especially testicular cancer), and other drug regimens (e.g., BEACOPP regimens) may also be used in the treatment of advanced hodgkin lymphoma patients, and the like. As mature old medicine, the pharmacokinetics, safety and preparation process of the old medicine have fully researched data, and convenience is provided for the new use of the old medicine. Rabies is a highly fatal zoonotic infectious disease caused by rabies virus (Rabies Virus, RABV) infection, and once clinical symptoms appear, the mortality rate is nearly 100%. At present, rabies mainly depends on preventive vaccination before exposure and passive immunization by injecting rabies immunoglobulin after exposure, but for patients with neurological symptoms, no effective rabies treatment medicine is marketed, and clinical treatment methods mainly comprise symptomatic support treatment and immune regulation, and cannot effectively inhibit virus replication or clear viruses of the central nervous system. Therefore, the development of therapeutic drugs that are effective in inhibiting rabies virus replication, particularly central nervous system infections, is an urgent need and a significant challenge in the current rabies research field. Disclosure of Invention Aiming at the dilemma faced by the existing rabies treatment, the invention aims to provide a new application of etoposide in the medicine for treating rabies infection, and fills the blank of medicine for treating rabies central nervous system infection. The technical scheme of the invention is as follows: firstly, the invention provides application of etoposide in preparation of anti-rabies virus drugs. Further, the antiviral mode of the medicine comprises inhibiting the replication of rabies virus in intracellular nucleic acid and the expression of virus M protein. In a second aspect, the invention also provides a medicament for treating rabies, the medicament composition comprising etoposide. Further, the medicine for treating rabies also comprises pharmaceutically acceptable auxiliary materials and carriers. Further, the auxiliary material is selected from at least one of filler, disintegrating agent, adhesive, excipient, diluent, lubricant, sweetener or colorant. Further, the dosage form of the medicine is at least one selected from granules, tablets, pills, capsules, injections or dispersing agents. Experiments prove that the anti-tumor drug etoposide shows remarkable anti-rabies virus activity at both cellular and animal levels for the first time. Etoposide can effectively inhibit the replication of rabies virus in neurogenic cells in vitro, and etoposide treatment can obviously improve the survival rate of mice infected with rabies virus in vivo. Therefore, the etoposide provides a brand new strategy and candidate medicaments for anti-rabies treatment and has great development and application prospects. Drawings In order to more clearly illustrate the embodiments of the present application or the technical solutions in the prior art, the drawings required for the embodiments will be briefly described below, and it is apparent that the drawings in the following description are only some embodiments